Pharmacokinetic consequences of time-dependent inhibition using the isolated perfused rat liver model

References

• Atkinson A, Kenny JR, Grime K. Automated assessment of the time-dependent inhibition of human cytochrome P450 enzymes using liquid chromatography-tandem mass spectrometry analysis. Drug Metabolism and Disposition 2005; 33: 1637–1647
   PubMed Web of Science ®Google Scholar
• Austin RP, Barton P, Mohmed S, Riley RJ. The binding of drugs to hepatocytes and its relationship to physiochemical properties. Drug Metabolism and Disposition 2005; 33: 419–425
   PubMed Web of Science ®Google Scholar
• Boxenbaum H. Cytochrome P450 3A4 in vivo ketoconazole competitive inhibition: Determination of Ki and dangers associated with high clearance drugs in general. Journal of Pharmacy and Pharmaceutical Sciences 1999; 2: 47–52
   PubMed Web of Science ®Google Scholar
• Corpier CL, Jones PH, Suki WN, Lederer ED, Quinones MA, Schmidt SW, Young JB. Rhabdomyolysis and renal injury with lovastatin use. Report of two cases in cardiac transplant recipients. Journal of the American Medical Association 1988; 260: 239–241
   PubMed Web of Science ®Google Scholar
• Curtis CG, Powell GM, Stone SL. Perfusion of the isolated rat liver. Journal of Physiology 1971; 213: 14P–15P
   PubMed Web of Science ®Google Scholar
• Dresser GK, Spence JD, Bailey DG. Pharmacokinetic–pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clinical Pharmacokinetics 2000; 38: 41–57
   PubMed Web of Science ®Google Scholar
• Eeckhoudt SL, Horsmans Y, Verbeeck RK. Differential induction of midazolam metabolism in the small intestine and liver by oral and intravenous dexamethasone pretreatment in rat. Xenobiotica 2002; 32: 975–984
   PubMed Web of Science ®Google Scholar
• Ernest CS, II, Hall SD, Jones DR. Mechanism-based inactivation of CYP3A by HIV protease inhibitors. Journal of Pharmacology and Experimental Therapeutics 2005; 312: 583–591
   PubMed Web of Science ®Google Scholar
• Hollenberg PF. Characteristics and common properties of inhibitors, inducers, and activators of CYP (cytochrome P 450) enzymes. Drug Metabolism Reviews 2002; 34: 17–35
   PubMed Web of Science ®Google Scholar
• Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR, Jr. Changes in the pharmacokinetics and electrocardiograph pharmacodynamics of terfenadine with concomitant administration of erythromycin. Clinical Pharmacology and Therapeutics 1992; 52: 231–238
   PubMed Web of Science ®Google Scholar
• Ishigam M, Uchiyama M, Kondo T, Iwabuchi H, Inoue SI, Takasaki W, Ikeda T, Komai T, Ito K, Sugiyama Y. Inhibition of in vitro metabolism of simvastatin by itraconazole in humans and prediction of in vivo drug–drug interactions. Pharmaceutical Research 2001; 18: 622–631
   PubMed Web of Science ®Google Scholar
• Ito K, Brown HS, Houston JB. Database analyses for the prediction of in vivo drug–drug interactions from in vitro data. British Journal of Clinical Pharmacology 2004; 57: 473–486
   PubMed Web of Science ®Google Scholar
• Ito K, Ogihara K, Kanamitsu S, Itoh T. Prediction of the in vivo interaction between midazolam and macrolides based on in vitro studies using human liver microsomes. Drug Metabolism and Disposition 2003; 31: 945–954
   PubMed Web of Science ®Google Scholar
• Iwatsubo T, Hirota N, Ooie T, Suzuki H, Sugiyama Y. Prediction of in vivo drug disposition from in vitro data based on physiological pharmacokinetics. Biopharmaceutics and Drug Disposition 1996; 17: 273–310
   PubMed Web of Science ®Google Scholar
• Jones DR, Hall SD. Mechanism-based inhibition of human cytochromes P 450: in vitro kinetics and in vitro–in vivo correlations. Drugs and the Pharmaceutical Sciences 2002; 116: 387–413
   Google Scholar
• Kanamitsu SI, Ito K, Green CE, Tyson CA, Shimada N, Sugiyama Y. Prediction of in vivo interaction between triazolam and erythromycin based on in vitro studies using human liver microsomes and recombinant human CYP3A4. Pharmaceutical Research 2000; 17: 419–426
   PubMed Web of Science ®Google Scholar
• Kantola T, Kivisto KT, Neuvonen PJ. Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations. Clinical Pharmacology and Therapeutics 1998; 64: 177–182
   PubMed Web of Science ®Google Scholar
• Khan KK, He YQ, Correia MA, Halpert JR. Differential oxidation of mifepristone by cytochromes P450 3A4 and 3A5: Selective inactivation of P450 3A4. Drug Metabolism and Disposition 2002; 30: 985–990
   PubMed Web of Science ®Google Scholar
• Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: A meta-analysis of prospective studies. Journal of the American Medical Association 1998; 279: 1200–1205
   PubMed Web of Science ®Google Scholar
• Mayhew BS, Jones DR, Hall SD. An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation. Drug Metabolism and Disposition 2000; 28: 1031–1037
   PubMed Web of Science ®Google Scholar
• Olkkola KT, Aranko K, Luurila H, Hiller A, Saarnivaara L, Himberg JJ, Neuvonen PJ. A potentially hazardous interaction between erythromycin and midazolam. Clinical Pharmacology and Therapeutics 1993; 53: 298–305
   PubMed Web of Science ®Google Scholar
• Phillips JP, Antal EJ, Smith RB. A pharmacokinetic drug interaction between erythromycin and triazolam. Journal of Clinical Psychopharmacology 1986; 6: 297–299
   PubMed Web of Science ®Google Scholar
• Seglen PO. Preparation of isolated rat liver cells. Methods in Cell Biology 1976; 13: 29–83
   PubMedGoogle Scholar
• Shiraki H, Guengerich FP. Turnover of membrane proteins: Kinetics of induction and degradation of seven forms of rat liver microsomal cytochrome P-450, NADPH-cytochrome P-450 reductase, and epoxide hydrolase. Archives of Biochemistry Biophysics 1984; 235: 86–96
   PubMed Web of Science ®Google Scholar
• Venkatakrishnan K, Von Moltke LL, Obach RS, Greenblatt DJ. Drug metabolism and drug interactions: Application and clinical value of in vitro models. Current Drug Metabolism 2003; 4: 423–459
   PubMed Web of Science ®Google Scholar
• Wang YH, Jones DR, Hall SD. Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metabolism and Disposition 2004; 32: 259–266
   PubMed Web of Science ®Google Scholar
• Warot D, Bergougnan L, Lamiable D, Berlin I, Bensimon G, Danjou P, Puech AJ. Troleandomycin–triazolam interaction in healthy volunteers: Pharmacokinetic and psychometric evaluation. European Journal of Clinical Pharmacology 1987; 32: 389–393
   PubMed Web of Science ®Google Scholar
• Wu CY, Benet LZ. Disposition of tacrolimus in isolated perfused rat liver: Influence of troleandomycin, cyclosporine, and GG918. Drug Metabolism and Disposition 2003; 31: 1292–1295
   PubMed Web of Science ®Google Scholar
• Yamano K, Yamamoto K, Katashima M, Kotaki H, Takedomi S, Matsuo H, Ohtani H, Sawada Y, Iga T. Prediction of midazolam-CYP3A inhibitors interaction in the human liver from in vivo/in vitro absorption, distribution, and metabolism data. Drug Metabolism and Disposition 2001; 29: 443–452
   PubMed Web of Science ®Google Scholar
• Zhou S, Chan E, Lee YL, Boelsterli UA, Li SC, Wang J, Zhang Q, Huang M, Xu A. Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4. Current Drug Metabolism 2004; 5: 415–442
   PubMed Web of Science ®Google Scholar
• Zhou S, Yung CS, Cher GB, Chan E, Duan W, Huang M, McLeod HL. Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clinical Pharmacokinetics 2005; 44: 279–304
   PubMed Web of Science ®Google Scholar
• Zimmermann M, Duruz H, Guinand O, Broccard O, Levy P, Lacatis D, Bloch A. Torsades de Pointes after treatment with terfenadine and ketoconazole. European heart Journal 1992; 13: 1002–1003
   PubMed Web of Science ®Google Scholar